Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Heron Therapeutics (HRTX) EBT Margin: 2010-2025

Historic EBT Margin for Heron Therapeutics (HRTX) over the last 11 years, with Sep 2025 value amounting to -10.71%.

  • Heron Therapeutics' EBT Margin rose 288.00% to -10.71% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.03%, marking a year-over-year increase of 1985.00%. This contributed to the annual value of -9.71% for FY2024, which is 7776.00% up from last year.
  • Per Heron Therapeutics' latest filing, its EBT Margin stood at -10.71% for Q3 2025, which was down 143.40% from -4.40% recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' EBT Margin registered a high of 10.23% during Q4 2024, and its lowest value of -269.43% during Q2 2021.
  • For the 3-year period, Heron Therapeutics' EBT Margin averaged around -36.04%, with its median value being -13.84% (2024).
  • As far as peak fluctuations go, Heron Therapeutics' EBT Margin plummeted by 5,272bps in 2021, and later spiked by 19,141bps in 2022.
  • Quarterly analysis of 5 years shows Heron Therapeutics' EBT Margin stood at -259.20% in 2021, then soared by 19,141bps to -67.79% in 2022, then skyrocketed by 3,793bps to -29.85% in 2023, then soared by 4,009bps to 10.23% in 2024, then spiked by 288bps to -10.71% in 2025.
  • Its EBT Margin stands at -10.71% for Q3 2025, versus -4.40% for Q2 2025 and 8.11% for Q1 2025.